Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Current Liabilities (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Total Current Liabilities for 8 consecutive years, with $92.2 million as the latest value for Q1 2026.

  • Quarterly Total Current Liabilities rose 2.46% to $92.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $92.2 million through Feb 2026, up 2.46% year-over-year, with the annual reading at $86.5 million for FY2025, 9.79% down from the prior year.
  • Total Current Liabilities for Q1 2026 was $92.2 million at Nurix Therapeutics, up from $86.5 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $95.9 million in Q4 2024, with the low at $61.5 million in Q3 2023.
  • Average Total Current Liabilities over 5 years is $78.8 million, with a median of $80.8 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities skyrocketed 55.12% in 2022, then fell 9.79% in 2025.
  • Over 5 years, Total Current Liabilities stood at $70.7 million in 2022, then increased by 23.07% to $87.0 million in 2023, then increased by 10.23% to $95.9 million in 2024, then dropped by 9.79% to $86.5 million in 2025, then rose by 6.62% to $92.2 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $92.2 million, $86.5 million, and $82.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.